Bridgewater, New Jersey (USA), March 24, 2016 – Amneal Pharmaceuticals LLC today
announced the launch of its first-to-market generic equivalent of Voltaren® Gel (diclofenac sodium
topical gel) 1% in the United States. Amneal recently received final approval from the U.S. Food
and Drug Administration for its Abbreviated New Drug Application for the product.
Amneal’s diclofenac sodium topical gel 1% is available in a 100g tube and is now shipping through
wholesalers, distributors and directly to the trade.

“We are very pleased to be the first generic supplier of diclofenac sodium topical gel,” said Chirag
Patel, Co-Chairman and Co-CEO. “This significant milestone continues to demonstrate our ability to
bring complex dosage forms to our customers and patients, and generates savings to the
healthcare system.”